First published in the Government *Gazette*, Electronic Edition, on 30 April 2020 at 5 pm.

No. S 350

MISUSE OF DRUGS ACT
(CHAPTER 185)

MISUSE OF DRUGS (AMENDMENT)
REGULATIONS 2020

In exercise of the powers conferred by section 58(1) of the Misuse of Drugs Act, the Minister for Home Affairs makes the following Regulations:

Citation and commencement

1. These Regulations are the Misuse of Drugs (Amendment) Regulations 2020 and come into operation on 1 May 2020.

Amendment of Second Schedule

2. Paragraph 10 of the Second Schedule to the Misuse of Drugs Regulations (Rg 1) is amended —

(*a*) by inserting, immediately after item (9), the following item:

"(9AAA) Crotonylfentanyl"; and

(*b*) by inserting, immediately after item (15), the following item:

"(16) Valerylfentanyl".

Amendment of Fourth Schedule

3. The Fourth Schedule to the Misuse of Drugs Regulations is amended —

(*a*) by deleting item (2) of paragraph 1 and substituting the following item:

"(2) 1-(4-Bromo-2,5-dimethoxyphenyl)propan-2-amine (also known as 4-Bromo-2,5-dimethoxy-α-methylphenethylamine,

4-Bromo-2,5-dimethoxyamphetamine, Brolamfetamine or DOB) and its bromo and dimethoxy positional isomers in the phenyl ring";

(*b*) by deleting item (12) of paragraph 1 and substituting the following item:

"(12) 1-(2,5-Dimethoxy-4-methylphenyl)propan-2-amine (also known as 2,5-Dimethoxy-4, α-dimethylphenethylamine, 2-Amino-1-(2,5-dimethoxy-4-methyl)phenylpropane or DOM) and its methyl and dimethoxy positional isomers in the phenyl ring";

(*c*) by deleting item (12A) of paragraph 15 and substituting the following item:

"(12A) 2-(Ethylamino)-1-phenylhexan-1-one (also known as N-Ethylhexedrone or Ethyl-hexedrone)";

(*d*) by inserting, immediately after item (24) of paragraph 15, the following item:

"(24A) 1-Phenyl-2-(pyrrolidin-1-yl)hexan-1-one (also known as Alpha-Pyrrolidinohexiophenone or Alpha-PHP or α-PHP)";

(*e*) by inserting, immediately after item (2) of paragraph 17, the following item:

"(2AAA) 6-Allyl-6-nor-lysergic acid diethylamide (also known as N-Allyl-nor-LSD or AL-LAD) and its acyclic secondary and tertiary amide structural isomers";

(*f*) by inserting, immediately after item (2A) of paragraph 17, the following item:

"(2AAB) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1H-indazole-3-carboxamide (also known as 2-[(1-Butyl-1H-indazol-3-yl)formamido]-3,3-dimethylbutanamide or ADB-BUTINACA) and its N-(1-amino-1-oxohexan-2-yl) isomers";

(*g*) by inserting, immediately after item (2CA) of paragraph 17, the following item:

"(2CB) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-hydroxybutyl)-1H-indazole-3-carboxamide and its

N-(1-amino-1-oxohexan-2-yl) isomers and their respective hydroxy positional isomers in the butyl group";

(*h*) by deleting item (2G) of paragraph 17 and substituting the following item:

"(2G) N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (also known as N-[1-Amino-3-methyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl) methyl]-1H-indazole-3-carboxamide or AB-FUBINACA) and its N-(1-amino-1-oxopentan-2-yl) and N-(1-amino-2-methyl-1-oxobutan-2-yl) isomers and their respective fluoro positional isomers in the phenyl ring";

(*i*) by inserting, immediately after item (6G) of paragraph 17, the following items:

"(6H) 1-Butanoyl-N,N-diethyllysergamide (also known as 1-Butanoyl-LSD or 1B-LSD) and its acyclic secondary and tertiary amide structural isomers

(6I) 2-(1-Butyl-1H-indazole-3-carboxamido)-3,3-dimethylbutanoic acid and its hexanoic acid isomers";

(*j*) by inserting, immediately after item (8A) of paragraph 17, the following item:

"(8AAA) 1-(4-Chloro-2,5-dimethoxyphenyl)propan-2-amine (also known as 4-Chloro-2,5-dimethoxy-α-methylphenethylamine, 4-Chloro-2,5-dimethoxyamphetamine, DOC, 3C-C, 4-Cl-2,5-DMA or 4-Chloro-2,5-DMA) and its chloro and dimethoxy positional isomers in the phenyl ring";

(*k*) by inserting, immediately after item (14) of paragraph 17, the following item:

"(14A) 2-[1-(4,5-Dihydroxypentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoic acid and its hexanoic acid isomers and their respective dihydroxy positional isomers in the pentyl group";

(*l*) by inserting, immediately after item (19AAB) of paragraph 17, the following item:

"(19AAC) 6-Ethyl-6-nor-lysergic acid diethylamide (also known as ETH-LAD) and its acyclic secondary and tertiary amide structural isomers";

(*m*) by inserting, immediately after item (19ABE) of paragraph 17, the following item:

"(19ABF) 2-Fluorodeschloroketamine (also known as 2-Fluoroketamine or 2-FDCK) and its fluoro positional isomers in the phenyl ring";

(*n*) by inserting, immediately after item (20AA) of paragraph 17, the following item:

"(20AB) 5-(5-Fluoropentyl)-2-(2-phenylpropan-2-yl)-pyrido [4,3-b]indol-1-one (also known as 2-Cumyl-5-(5-fluoropentyl)-gamma-carbolin-1-one or 5-Fluoro-cumyl-PEGACLONE) and its phenylpropyl isomers and their respective fluoro positional isomers in the pentyl group";

(*o*) by inserting, immediately after item (27DA) of paragraph 17, the following item:

"(27DB) Lysergic acid 2,4-dimethylazetidide (also known as LSZ)";

(*p*) by deleting item (28FA) of paragraph 17 and substituting the following item:

"(28FA) Methyl 2-[1-(4-fluorobutyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (also known as Methyl 2-{[1-(4-fluorobutyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate, 4F-MDMB-BINACA, 4F-MDMB-BUTINACA or 4-Fluoro-MDMB-BINACA) and its hexanoate isomers and their respective fluoro positional isomers in the butyl group";

(*q*) by deleting items (28H) and (28I) of paragraph 17 and substituting the following items:

"(28H) Methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3-methylbutanoate (also known as Methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3-methylbutanoate, 5F-AMP, 5-Fluoro-AMP, 5F-MMB-PINACA, 5F-AMB-PINACA, 5-Fluoro-AMB or

5-Fluoro-MMB-PINACA) and its pentanoate isomers and their respective fluoro positional isomers in the pentyl group

(28I) Methyl 2-[1-(5-fluoropentyl)-1H-indole-3-carboxamido]-3,3-dimethylbutanoate (also known as Methyl 2-{[1-(5-fluoropentyl)-1H-indole-3-carbonyl] amino}-3,3-dimethylbutanoate, 5F-MDMB-PICA, 5F-MDMB-2201, 5-Fluoro-MDMB-2201 or 5-Fluoro-MDMB-PICA) and its hexanoate isomers and their respective fluoro positional isomers in the pentyl group";

(*r*) by inserting, immediately after item (37) of paragraph 17, the following item:

"(37A) 2-[1-Pent-4-en-1-yl]-1H-indazole-3-carboxamido]-3,3-dimethylbutanoic acid and its hexanoic acid isomers and their respective pentenyl positional isomers in the pentyl group";

(*s*) by inserting, immediately after item (38) of paragraph 17, the following item:

"(38AAA) 1-Pentyl-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide (also known as Cumyl-PICA) and its phenylpropyl isomers"; and

(*t*) by inserting, immediately after item (38AA) of paragraph 17, the following items:

"(38AB) 5-{3-[(2-Phenylpropan-2-yl)carbamoyl]-1H-indol-1-yl}pentanoic acid and its phenylpropyl isomers

(38AC) 2-(2-Phenylpropan-2-yl)-5-pentyl-pyrido[4,3-b] indol-1-one (also known as 2-Cumyl-5-pentylgamma-carbolin-1-one or cumyl-PEGACLONE or SGT-151) and its phenylpropyl isomers

(38AD) 1-Propionyl-N,N-diethyllysergamide (also known as 1-Propionyl-LSD or 1P-LSD) and its acyclic secondary and tertiary amide structural isomers

(38AE) 6-Propyl-6-nor-lysergic acid diethylamide (also known as PRO-LAD) and its acyclic secondary and tertiary amide structural isomers".

[G.N. Nos. S 390/99; S 231/2000; S 436/2000; S 140/2001; S 492/2001; S 506/2005; S 490/2006; S 108/2007; S 525/2010; S 684/2010; S 270/2013; S 322/2014; S 571/2014; S 253/2015; S 199/2016; S 193/2017; S 234/2018; S 588/2018; S 88/2019; S 151/2019; S 353/2019; S 791/2019]

Made on 29 April 2020.

PANG KIN KEONG
Permanent Secretary,
Ministry of Home Affairs,
Singapore.

[MHA 112/2/0049; AG/LEGIS/SL/185/2020/7 Vol. 1]